Guangzhou Virotech Pharmaceutical Co., Ltd.

Jiankai Liang

Guangmei Yan

Jun Hu

Suizhen Lin

Kai Li

Yuan Lin

Haipeng Zhang

Xiao Xiao

Wei Yin

Wenbo Zhu

Jing Cai

Shoufang Gong

Yaqian Tan

The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.

Use of VCP inhibitor and oncolytic virus in the preparation of an anti-tumor drug

Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.

Use of alphavirus in preparation of antitumor drugs

Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.

Use of IAP inhibitor and oncolytic virus in preparation of anti-tumor drug

Growing community of inventors

Guangzhou, China

Jiankai Liang